THERAPEUTIC EFFECTS OF DAUNOMYCIN-CONJUGATED ANTI-α-FETPROTEIN ANTIBODIES ON RAT HEPATOMAS AFTER SELECTIVE REMOVAL OF α-FETPROTEIN IN PLASMA

概要

論文の詳細を見る
The therapeutic effects on hepatoma-bearing rats of daunomycin-conjugated anti-α-fetprotein (AFP) antibody, non-conjugated anti-AFP antibody, and anti-AFP serum after removal of AFP in plasma were investigated. Hepatomas were induced by 3'-methyl-4-dimethyl aminoazobenzene. The effects were estimated by the decrease of serum AFP level, since hepatoma size could not be directly measured before immunotherapy. The effects of anti-AFP serum were evidenced by the decrease of serum AFP level and shown to be enhanced when the anti-AFP serum was administered after removal of AFP from plasma. The administration of daunomycin-conjugated anti-AFP antibodies after this removal of AFP from plasma displayed the most distinct effect on the decrease of serum AFP level: Serum AFP concentration in this group was maintain at a low level longer than in any other group. These results indicate that the removal of plasma AFP before administration facilitates attachment of daunomycin-conjugated anti-AFP antibodies to tumor cells, and is probably followed by endocytosis and the cytotoxic effect of daunomycin. The removal of AFP from plasma is therefore an indispensable pretreatment. The administration of daunomycin-conjugated anti-AFP antibodies after removal of AFP from plasma is thus suggested to be one of the effective therapies for AFP-producing hepatomas.
名古屋市立大学の論文
1983-12-23